Sonntag, 16. Mai 2021
Navigation öffnen
Anzeige:
CAR T Prelaunch
CAR T Prelaunch
 
JOURNAL ONKOLOGIE – STUDIE
DLI-TARGET

Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab

Rekrutierend

NCT-Nummer:
NCT03982992

Studienbeginn:
Juni 2019

Letztes Update:
14.06.2019

Wirkstoff:
Blinatumomab in combination with donor lymphocyte infusion

Indikation (Clinical Trials):
Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Lymphoid, Neoplasm, Residual, Burkitt Lymphoma

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
Phase 2

Sponsor:
Ludwig-Maximilians - University of Munich

Collaborator:
Amgen

Studienleiter

Marion Subklewe, MD
Principal Investigator
Klinikum der Universität München
Christian Schmidt, MD
Principal Investigator
Klinikum der Universität München
Sascha Haubner, MD
Principal Investigator
Klinikum der Universität München

Kontakt

DLI-TARGET Investigator Team
Kontakt:
Phone: +49 (0)89 4400-73133
E-Mail: dli-target@med.uni-muenchen.de
» Kontaktdaten anzeigen
Christian Schmidt, MD
Kontakt:
Phone: +49 (0)89 4400-77907
E-Mail: Christian_Schmidt@med.uni-muenchen.de
» Kontaktdaten anzeigen

Studienlocations
(1 von 1)

Brustzentrum am Klinikum der Universität München
Marchioninistraße 15
80337 München
DeutschlandRekrutierend» Google-Maps
Ansprechpartner:
Marion Subklewe, MD
Phone: +49 (0)89 4400-73133
E-Mail: dli-target@med.uni-muenchen.de

Christian Schmidt, MD
Phone: +49 (0)89 4400-77907
E-Mail: Christian_Schmidt@med.uni-muenchen.de
» Ansprechpartner anzeigen

Studien-Informationen

Brief Summary:

This phase 2 study is designed to evaluate the safety, tolerability and efficacy of allogeneic donor lymphocyte infusions (DLI) combined with the bispecific T cell engager blinatumomab in B-precursor ALL patients who have mixed chimerism (MC) or are MRD-positive after allogeneic SCT and are refractory to at least one MRD- or MC-targeted therapy (i.e. blinatumomab, DLI, tyrosine kinase inhibitors or other agents).

Ein-/Ausschlusskriterien

Inclusion Criteria:

1. Adult patients with CD19+ B-precursor ALL (as determined by immunophenotyping) in hCR (defined as having less than 5% blasts in bone marrow) after allogeneic SCT.

2. One, or a combination of the following documented after an interval of at least 2 weeks since cessation of the most recent leukemia-targeting therapy (i.e. chemotherapy, immunotherapy or cellular therapy, except for intrathecal prophylaxis):

- Positivity for CD19+ MRD (molecular failure or molecular relapse), defined as presence of MRD at a level of ≥10^-4 according to an assay with a minimum sensitivity of 10^-4.

- Donor chimerism <90%, as determined by analysis of host and donor STRs in bone marrow sample engraftment analysis.

3. At least one previous line of treatment for MRD-positivity and/or reduced donor chimerism (i.e. blinatumomab, DLI, TKI or other agents) after allogeneic SCT.

4. For those with BCR/ABL-positive B-precursor ALL only: persistence of MRD and/or MC following at least one ≥ second generation TKI (dasatinib, nilotinib, bosutinib, ponatinib) OR intolerance to second generation TKI and intolerance to or persistence of MRD and/or MC following imatinib mesylate.

5. Availability of allogeneic donor lymphocytes from the subject's donor (at least 2 x 10^8 T cells/kg).

6. Subject has provided written informed consent prior to initiation of any study-specific activities/procedures.

7. Subject has provided informed consent to be followed up in the GMALL-Registry.

8. Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2.

9. Renal function as follows: serum creatinine < 2.0 mg/dL and estimated glomerular filtration rate > 30 mL/min.

10. Hepatic function as follows:

- Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤ 3.0 x upper limit of normal (ULN)

- Alkaline phosphatase (ALP) < 3.0 x ULN

- Bilirubin ≤ 2.0 x ULN (unless considered due to Gilbert's syndrome or hemolysis)

11. For female subjects only: Women of child-bearing age have to use a reliable method of contraception.

Exclusion Criteria:

1. Eligibility for treatment with blinatumomab ALONE or other antibody-based treatment approaches (e.g. inotuzumab ozogamicin), as considered by the treating physician.

2. Eligibility for standard chemotherapy, as considered by the treating physician.

3. Antitumor therapy (chemotherapy, antibody therapy, molecular-targeted therapy, retinoid therapy, or investigational agent) within 14 days or 5 half-lives (whichever is longer) prior to baseline MRD and/or chimerism assessment.

4. Treatment with systemic immune modulators including, but not limited to, non-topical systemic corticosteroids, cyclosporine, and tacrolimus within 2 weeks before enrollment.

5. Any grade of GvHD currently requiring treatment.

6. Clinically relevant central nervous system (CNS) pathology requiring treatment (e.g., unstable epilepsy).

7. Evidence of current CNS involvement by ALL.

Studien-Rationale

Primary outcome:

1. Safety and tolerability of combined DLI and blinatumomab treatment in subjects with treatment-resistant MC or MRD of CD19+ B-precursor ALL after allogeneic SCT (Time Frame - 18 weeks):
Subject incidence and grade of adverse events (AEs) including graft-versus-host disease (GvHD). The intensity of (S)AEs will be assessed according to the NCI Common Terminology Criteria for Adverse Events (CTCAE), version 4.03.



Secondary outcome:

1. Efficacy of a combined treatment of DLI and blinatumomab to induce a complete MRD/chimerism response (Time Frame - 18 weeks):
MRD response based on RT-PCR: Complete MRD response (MolCR): hCR and MRD not detectable by molecular probe[s] with a sensitivity ≥10−4. The MRD response is calculated as: [number of patients achieving complete MRD response after at least one cycle (minimum 4 days blinatumomab) of study treatment] / [number of patients who received at least 1 cycle (minimum 4 days blinatumomab) of study treatment]. Mixed chimerism response: CC response: only donor STRs in bone marrow; Low-level MC response ≥90% but <100% donor STRs in bone marrow. The MC response is calculated as: [number of patients achieving CC/low-level MC response after at least one cycle (minimum 4 days blinatumomab) of study treatment] / [number of patients who received at least 1 cycle (minimum 4 days blinatumomab) of study treatment].

2. Duration of the response and survival after combined treatment of DLI and blinatumomab (Time Frame - 18 weeks):
For patients who received at least one cycle (minimum 4 days of blinatumomab), progression-free survival and overall survival will be calculated using kaplan-meier survival estimates. Descriptive summary statistics (N, mean, standard deviation, minimum, median and maximum) for the duration of response will be performed for all patients with an observed complete MRD response or CC/low-level MC response.

Geprüfte Regime

  • Blinatumomab in combination with donor lymphocyte infusion:
    Continuous blinatumomab infusion in combination with allogeneic donor lymphocyte infusion

Quelle: ClinicalTrials.gov


Das könnte Sie auch interessieren
Klinische Studien in der Krebstherapie – Informationen für Patienten
Klinische+Studien+in+der+Krebstherapie+%E2%80%93+Informationen+f%C3%BCr+Patienten
© Alexander Raths / Fotolia.com

Für Krebspatienten ist die Teilnahme an einer Studie mit der Chance verbunden, frühzeitig Zugang zu innovativen Behandlungsmethoden zu bekommen, die im klinischen Alltag nicht erhältlich sind. Neue Wirkstoffe bieten viele Chancen, können aber auch unbekannte Risiken und Nebenwirkungen mit sich bringen. Das ONKO-Internetportal erläutert, welche Arten von Studien es in der Krebstherapie gibt und was Patienten, die sich...

Personalisierte Medizin in der Onkologie: Behandlung bestmöglich auf den Patienten zuschneiden

Medikamente möglichst maßgeschneidert auf die spezifischen Merkmale einer Krankheit zuzuschneiden und diese gezielt bei jenen Patienten einzusetzen, denen sie am besten helfen, lautet das Credo der Personalisierten Medizin. Dank vertiefter Kenntnisse über die molekularbiologischen Ursachen von Krankheiten gibt es heute bereits eine Reihe von innovativen diagnostischen Tests, durch die Patienten identifiziert werden...

Hufeland-Preis ehrt Initiatoren eines bundesweiten Kita-Sonnenschutzprojekts zur Krebsprävention
Hufeland-Preis+ehrt+Initiatoren+eines+bundesweiten+Kita-Sonnenschutzprojekts+zur+Krebspr%C3%A4vention
© drubig-photo / Fotolia.com

Prof. Eckhard Breitbart, Vorsitzender der Arbeitsgemeinschaft für Dermatologische Prävention e.V. (ADP), Dr. Nadja Seidel und Dr. Friederike Stölzel, Leiterinnen des Präventionszentrums des Nationalen Centrums für Tumorerkrankungen Dresden (NCT/UCC) sind mit dem Hufeland-Preis des Kuratoriums der Stiftung Hufeland-Preis ausgezeichnet worden. Sie erhielten den mit 20.000 Euro dotierten Preis für...

Darmkrebspatienten benötigen spezialisierte Anlaufstelle und Interessenvertretung
Darmkrebspatienten+ben%C3%B6tigen+spezialisierte+Anlaufstelle+und+Interessenvertretung
© Fotolia / cryonoid_media

Mit einem Pressegespräch am 19. April in Berlin nimmt EuropaColon Deutschland e. V. seine Tätigkeit als spezialisierte Anlaufstelle und Interessenvertretung von Darmkrebspatienten auf. Der neu gegründete Verein ist die deutsche Tochter der seit zwölf Jahren europaweit aktiven Patientenorganisation EuropaColon, die in 24 Ländern Europas Menschen mit Darmkrebs unterstützt und gegenüber der Gesundheitspolitik für deren...